Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | MMP13 | P45452 | 10/20 | 0.40 |
| ▸ | MMP14 | P50281 | 3/20 | 0.40 |
| ▸ | MMP12 | P39900 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | ADAM17 | P78536 | 3/20 | 0.34 |
| ▸ | MMP2 | P08253 | 1/20 | 0.34 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.34 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL940446 | 0.88 | ALDH1A1 (0.57) | ALDH1A1MMP13MMP14SMN1; SMN2NPSR1 | |
| SCHEMBL944078 | 0.88 | ALDH1A1 (0.57) | ALDH1A1MMP13MMP14SMN1; SMN2NPSR1 | |
| SCHEMBL941900 | 0.88 | ALDH1A1 (0.57) | ALDH1A1MMP13MMP14SMN1; SMN2NPSR1 | |
| SCHEMBL74108 | 0.78 | MMP13 (0.41) | ALDH1A1MMP13MMP14MMP12SMN1; SMN2 | |
| SCHEMBL75900 | 0.78 | MMP13 (0.41) | ALDH1A1MMP13MMP14MMP12SMN1; SMN2 | |
| SCHEMBL2967822 | 0.78 | MMP13 (0.41) | ALDH1A1MMP13MMP14MMP12SMN1; SMN2 | |
| SCHEMBL8661339 | 0.71 | ALDH1A1 (0.42) | ALDH1A1SMN1; SMN2ADAM17MAPT | |
| SCHEMBL13103908 | 0.70 | ALDH1A1 (0.42) | ALDH1A1MMP13ADAM17MMP2MAPT | |
| SCHEMBL5935684 | 0.70 | ALDH1A1 (0.42) | ALDH1A1MMP13ADAM17MMP2MAPT | |
| SCHEMBL1099764 | 0.69 | ALDH1A1 (0.48) | ALDH1A1MMP13MMP14SMN1; SMN2NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1676846-B1 | Hydantoin derivatives as MMP inhibitors | ASTRAZENECA AB (SE) | 2010-12-29 | — | — | EP | disclosed |
| US-20100273849-A1 | Metalloproteinase Inhibitors | ASTRAZENECA AB (SE) | 2010-10-28 | — | — | US | disclosed |
| EP-1370537-B1 | METALLOPROTEINASE INHIBITORS | ASTRAZENECA AB (SE) | 2010-10-13 | — | — | EP | disclosed |
| US-7754750-B2 | a -5 substituted 1-H,3-H-imidazolidine-2,4-dione such as 5-(2-{[4-(4'-fluoro[1,1'-biphenyl]-4-yl)-1-piperazinyl]sulfonyl}ethyl)-2,4-imidazolidinedione; protease inhibitors, especially metalloelastase (MMP12) | ASTRAZENECA AB (SE) | 2010-07-13 | — | — | US | disclosed |
| US-7666892-B2 | Metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2010-02-23 | — | — | US | disclosed |
| US-7625934-B2 | Metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2009-12-01 | — | — | US | disclosed |
| US-20080306065-A1 | Metalloproteinase Inhibitors | ASTRAZENECA AB (SE) | 2008-12-11 | — | — | US | disclosed |
| US-20080262045-A1 | Metalloproteinase Inhibitors | ASTRAZENECA AB (SE) | 2008-10-23 | — | — | US | disclosed |
| US-7427631-B2 | especially as inhibitors of MMP12 | ASTRAZENECA AB (SE) | 2008-09-23 | — | — | US | disclosed |
| US-20080171882-A1 | Metalloproteinase Inhibitors | ASTRAZENECA AB (SE) | 2008-07-17 | — | — | US | disclosed |
| US-7368465-B2 | Respiratory system disorders; antiarthritic agents; anticancer agents; bone disorders | ASTRAZENECA AB (SE) | 2008-05-06 | — | — | US | disclosed |
| EP-1370556-B1 | METALLOPROTEINASE INHIBITORS | ASTRAZENECA AB (SE) | 2006-07-19 | — | — | EP | disclosed |
| EP-1676846-A2 | Hydantoin derivatives as MMP inhibitors | AstraZeneca AB (SE) | 2006-07-05 | — | — | EP | disclosed |
| US-20040127528-A1 | Metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2004-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306065-A1 | Metalloproteinase Inhibitors | MMP9, MMP12, MMP14 | ALDH1A1 612/4885MMP13 12/4885MMP14 3/4885 |
| US-20100273849-A1 | Metalloproteinase Inhibitors | MMP9, MMP12, MMP11 | ALDH1A1 1381/4885MMP13 6/4885MMP14 10/4885 |
| US-20080171882-A1 | Metalloproteinase Inhibitors | MMP9, MMP12, MMP14 | ALDH1A1 612/4885MMP13 12/4885MMP14 3/4885 |
| US-20080262045-A1 | Metalloproteinase Inhibitors | MMP9, MMP12, MMP11 | ALDH1A1 1381/4885MMP13 6/4885MMP14 10/4885 |
| US-20040127528-A1 | Metalloproteinase inhibitors | MMP9, MMP10, MMP3 | ALDH1A1 573/4885MMP13 10/4885MMP14 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.